Neuronetics has recently completed patient enrollment for its series of clinical trials investigating transcranial magnetic stimulation (TMS) for the treatment of major depression. The trials are being conducted at multiple US and international locations and have enrolled over 300 patient volunteers. The acute phase trial which is randomized, double blind, and sham controlled is designed to assess the safety and efficacy of TMS delivered by the Neuronetics TMS system in the treatment of major depression. An additional trial is designed to evaluate the durability of any positive TMS treatment effects. Results of these studies will be available in early 2006. Professionals interested in receiving updates on the possible availability of TMS should send their name, institutional affiliation (if any) and email address to contact@neuronetics.com.

If you would like to learn more about the clinical trials now fully enrolled, please go to View Clinical Trial Specifics